DreaMed Diabetes
DreaMed Diabetes is an Israel-based AI software company founded in 2014 that builds a clinical decision-support platform converting continuous glucose monitoring data into expert-level insulin treatment recommendations for healthcare providers and diabetes patients, integrated with Abbott FreeStyle Libre CGM devices and deployed into U.S. health systems.
- Company typePrivate
- Founded2014
- HeadquartersPetah Tiqva, Israel
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
What DreaMed Diabetes does
DreaMed Diabetes Ltd. is an Israel-based, venture-backed software company founded in 2014 that builds an AI-driven clinical decision-support platform for diabetes management. The platform ingests continuous glucose monitoring (CGM) data — most notably from Abbott's FreeStyle Libre devices via a data integration partnership signed in August 2024 — alongside other patient data, and outputs expert-level insulin treatment recommendations intended for use by healthcare providers and patients. Its founding leadership combines deep clinical diabetes research credentials (CSO Moshe Phillip, Chief Medical R&D Officer Revital Nimri) with product and engineering talent, and the company has been funded by strategic and impact-oriented investors including Medtronic ($2M, 2015), Millhouse ($3.3M, 2016), The Helmsley Charitable Trust ($5M, 2020), and most recently eHealth Ventures ($3M lead, 2024).
DreaMed generates revenue through what appears to be a B2B enterprise software model — subscription or licensing of its AI platform to healthcare systems and device partners — though pricing is not publicly disclosed. Its go-to-market combines enterprise field sales into U.S. healthcare providers (e.g., Yale New Haven Health) with API-first integration partnerships that embed its dosing algorithms into medical-device ecosystems. The company operates at small scale (11-50 employees, headquartered in the Tel Aviv / Petah Tiqva area) and is at an early commercial stage, having only recently converted its first two publicly named commercial relationships. The corporate website now redirects to dreamed.ai, suggesting a possible broader rebrand or platform expansion beyond diabetes.
Strategically, DreaMed is positioning itself as the AI dosing and decision-support layer for the global automated insulin delivery market — a market valued at approximately $989M in 2025 and projected to grow at a 10.5% CAGR to roughly $2.7B by 2035. Its near-term priorities, as stated in the August 2024 funding announcement, are U.S. expansion, platform improvement, and deepening partnerships with device makers and health systems. The combination of clinical-research depth, anchor partnerships with category leaders, and a focused TAM positioning is the company's primary investment thesis, tempered by small scale, undisclosed revenue, and limited public validation of its AI models.
DreaMed Diabetes firmographics
Firmographics- Name
- DreaMed Diabetes
- Legal name
- DreaMed Diabetes Ltd.
- Website
- https://dreamed-diabetes.com
- Company type
- Private
- Founded year
- 2014
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- DreaMed Diabetes is an Israel-based AI software company founded in 2014 that builds a clinical decision-support platform converting continuous glucose monitoring data into expert-level insulin treatment recommendations for healthcare providers and diabetes patients, integrated with Abbott FreeStyle Libre CGM devices and deployed into U.S. health systems.
- Ownership category
- akta.pro rank
DreaMed Diabetes industry classification
Industry- Product category
- AI Diabetes Management Software
- NAICS
- Software Publishers (513210)
- SIC
- Services-Prepackaged Software (7372)
- akta.pro primary industry
- Diabetes Digital Therapeutics & Dose Decision Support (Bolus Calculators) (HLAHAHAJ)
- akta.pro secondary industries
- Continuous Glucose Monitoring (CGM) Systems (HLAHAHAA), Connected Therapeutics & Smart Drug Delivery Monitoring (HLACAFAL), Type 1 Diabetes Care (HLAKADAB)
Keywords
Where DreaMed Diabetes is headquartered
LocationHeadquarters
- HQ city
- Petah Tiqva
- HQ country
- Israel
- HQ region
- Middle East
Offices1 record
Markets served
DreaMed Diabetes business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Marketing or Sales, Operations
Revenue model
- AI-Driven Diabetes Care Platform: Software platform providing AI-driven diabetes care solutions for healthcare providers and patients, with revenue likely generated through subscription licensing or per-patient usage fees
Go-to-market motion2 records
Distribution channels1 record
DreaMed Diabetes product offering
Product offeringCore offering
DreaMed Diabetes builds an AI-driven software platform that transforms continuous glucose monitoring (CGM) and other patient data into expert-level insulin treatment recommendations. The platform integrates with CGM devices such as Abbott's FreeStyle Libre to provide clinical decision support and automated insulin therapy optimization for healthcare providers and diabetes patients.
Product overview
DreaMed Diabetes offers a unified AI-driven software platform for diabetes care management. The core product is an AI platform that transforms continuous glucose monitoring and patient data into expert-level insulin treatment recommendations, enabling automated diabetes management and clinical decision support for healthcare providers.
Differentiator
Problem solved
Functional benefit
Products and services
- DreaMed AI-Driven Diabetes Care Platform An AI-driven platform for diabetes treatment that transforms patient data into expert-level insulin treatment recommendations. The platform integrates with continuous glucose monitoring devices and provides clinical decision support for diabetes management, aimed at healthcare providers and patients.
Companies that use DreaMed Diabetes
Customer profileNamed customers2 records
Segments1 record
Ideal customer profiles2 records
DreaMed Diabetes technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration1 record
AI capability4 records
Feature2 records
DreaMed Diabetes partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core.
- AbbottcoreData integration partnership enabling data sharing from Abbott's FreeStyle Libre CGM devices to DreaMed's AI platform. This integration allows continuous glucose monitoring data to flow directly into DreaMed's diabetes treatment system for AI-driven insulin optimization.
- Yale New Haven HealthcoreHealthcare system partnership for building collaborative relationships in diabetes care. DreaMed is developing partnerships with Yale New Haven Health to integrate AI-driven diabetes care solutions into clinical workflows.
Scale indicators3 records
Recent moves6 records
Expansion highlights5 records
DreaMed Diabetes competitors and assessment
Company assessmentOthers
- Abbott Diabetes Care: Abbott's FreeStyle Libre is the CGM franchise that DreaMed integrates with. While not a direct competitor in dose advice, Abbott's strategic direction on whether to build or buy AI dosing is a critical determinant of DreaMed's trajectory.
Broad incumbents
- Roche Diabetes Care: Roche's Accu-Chek smart insulin pen and mySugr app bundle connected diabetes management. A broad incumbent offering connected insulin delivery and decision support that overlaps with DreaMed's clinical workflow positioning.
- Insulet: Insulet's Omnipod 5 integrates an automated insulin delivery algorithm directly into its tubeless pump. A relevant incumbent showing how dosing AI is increasingly bundled with hardware.
- Tandem Diabetes Care: Tandem's Control-IQ technology is an AI-based automated insulin dosing algorithm integrated into its t:slim pump. Represents the bundled, hardware-attached approach that competes with DreaMed's standalone AI dose advisor.
- Medtronic: Medtronic's MiniMed 780G is an AI-driven closed-loop AID system with embedded dosing algorithms. As a former DreaMed investor and a major incumbent in diabetes technology, it represents both a partner/competitor dynamic relevant to DreaMed's positioning.
Direct peers
- Bigfoot Biomedical: Bigfoot Unity offers AI-driven insulin dose decision support via a smart pen cap system. Directly comparable to DreaMed as a connected, AI-first diabetes therapy optimization platform targeting similar patients and providers.
- Diabeloop: Diabeloop develops an AI-based automated insulin delivery and decision-support algorithm embedded in pump systems. Highly comparable to DreaMed's AI insulin recommendation engine, with the same patient population and clinical use case.
- CamDiab (CamAPS FX): CamDiab's CamAPS algorithm is an AI-driven closed-loop dosing app for people with Type 1 diabetes. Direct peer in AI-based personalized insulin therapy decision support.
- Hygieia (d-Nav): Hygieia's d-Nav is an AI insulin dose adjustment service for Type 2 diabetes patients, similar in function to DreaMed's AI insulin treatment recommendations and serving an overlapping provider base.
Emerging players
- Beta Bionics: Beta Bionics' iLet bionic pancreas uses algorithmic insulin dosing with minimal user input. Comparable emerging competitor in the AI-driven insulin decision support space.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat5 records
Key risks5 records
Key highlights6 records
Customer concentration
DreaMed Diabetes social profiles
Digital presenceDreaMed Diabetes financial estimates
Financial estimateRevenue estimate
Valuation estimate
DreaMed Diabetes leadership team
Management profileNumber of profiles
Profiles1 record
DreaMed Diabetes funding detail
Funding detailFunding overview
Funding rounds5 records
Investors5 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
DreaMed Diabetes M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about DreaMed Diabetes
What does DreaMed Diabetes do?
DreaMed Diabetes builds an AI-driven software platform that transforms continuous glucose monitoring (CGM) and other patient data into expert-level insulin treatment recommendations. The platform integrates with CGM devices such as Abbott's FreeStyle Libre to provide clinical decision support and automated insulin therapy optimization for healthcare providers and diabetes patients.
Is DreaMed Diabetes a public or private company?
DreaMed Diabetes is a private company. It is classified as venture growth investor backed and is currently operating.
When was DreaMed Diabetes founded?
DreaMed Diabetes was founded in 2014. It employs 11 to 50 people.
Where is DreaMed Diabetes based?
DreaMed Diabetes is headquartered in Petah Tiqva, Israel, in the Middle East region.
How does DreaMed Diabetes make money?
One revenue line is on record: AI-Driven Diabetes Care Platform.
Who are DreaMed Diabetes's main competitors?
Abbott Diabetes Care is listed as an others. Broad incumbents are Roche Diabetes Care, Insulet, Tandem Diabetes Care and Medtronic. Direct peers are Bigfoot Biomedical, Diabeloop, CamDiab (CamAPS FX) and Hygieia (d-Nav). Beta Bionics is listed as an emerging player.
Does DreaMed Diabetes have an API?
No public API is recorded for DreaMed Diabetes.
What industry is DreaMed Diabetes in?
DreaMed Diabetes's product category is AI Diabetes Management Software. Its primary akta.pro industry code is HLAHAHAJ, Diabetes Digital Therapeutics & Dose Decision Support (Bolus Calculators), with a secondary code of HLAHAHAA, Continuous Glucose Monitoring (CGM) Systems. Its NAICS code is 513210 and its SIC code is 7372.